FDA approves X4 Pharmaceuticals' therapy for immunodeficiency disease

X4 Pharmaceuticals (XFOR.O) said on Monday the U.S. FDA has approved its therapy to treat a rare genetic immunodeficiency disease in patients 12 years of age and older.